Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers
Research output: Contribution to journal › Journal article › Research › peer-review
- Clinical Research, Department of , Nordsjællands Hospital
- Oncology and Palliative Care, Department of , Nordsjællands Hospital
- Clinical Immunology, Centre of Diagnostic Investigations
- Clinical Biochemistry, Department of , Nordsjællands Hospital
- Gynaecology and Obstetrics, Department of , Nordsjællands Hospital
INTRODUCTION: Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals.
METHODS: We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals.
RESULTS: SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%).
CONCLUSION: Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.
FUNDING: The assays performed at Rigshospitalet were developed with financial support from the Carlsberg Foundation (CF20-0045) and the Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201).
TRIAL REGISTRATION: The study was registered with the Danish National Committee on Health Research Ethics (H-20022312).
| Original language | English |
|---|---|
| Article number | A11210843 |
| Journal | Danish Medical Journal |
| Volume | 69 |
| Issue number | 5 |
| ISSN | 1603-9629 |
| Publication status | Published - 7 Apr 2022 |
Bibliographical note
Articles published in the DMJ are “open access”. This means that the articles are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- Antibodies, Viral, COVID-19/epidemiology, Health Personnel, Humans, Pandemics, Prevalence, SARS-CoV-2, Seroepidemiologic Studies
Research areas
ID: 77626405